Inovio shares rise after positive FDA feedback on RRP treatment candidate

Biotechnology company Inovio saw its shares jump after the US FDA communicated that data from Inovio completed Phase 1/2 trial of INO-3107 for treating...

Related Keywords

United States ,New York , ,Recurrent Respiratory Papillomatosis ,Biological License Application ,Breakthrough Therapy Designation ,